<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34416191</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2619</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Respiratory medicine</Title><ISOAbbreviation>Lancet Respir Med</ISOAbbreviation></Journal><ArticleTitle>The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease.</ArticleTitle><Pagination><StartPage>1467</StartPage><EndPage>1478</EndPage><MedlinePgn>1467-1478</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-2600(21)00286-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-2600(21)00286-1</ELocationID><Abstract><AbstractText>Persistent ill health after acute COVID-19-referred to as long COVID, the post-acute COVID-19 syndrome, or the post-COVID-19 condition-has emerged as a major concern. We undertook an international consensus exercise to identify research priorities with the aim of understanding the long-term effects of acute COVID-19, with a focus on people with pre-existing airways disease and the occurrence of new-onset airways disease and associated symptoms. 202 international experts were invited to submit a minimum of three research ideas. After a two-phase internal review process, a final list of 98 research topics was scored by 48 experts. Patients with pre-existing or post-COVID-19 airways disease contributed to the exercise by weighting selected criteria. The highest-ranked research idea focused on investigation of the relationship between prognostic scores at hospital admission and morbidity at 3 months and 12 months after hospital discharge in patients with and without pre-existing airways disease. High priority was also assigned to comparisons of the prevalence and severity of post-COVID-19 fatigue, sarcopenia, anxiety, depression, and risk of future cardiovascular complications in patients with and without pre-existing airways disease. Our approach has enabled development of a set of priorities that could inform future research studies and funding decisions. This prioritisation process could also be adapted to other, non-respiratory aspects of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adeloye</LastName><ForeName>Davies</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elneima</LastName><ForeName>Omer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daines</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poinasamy</LastName><ForeName>Krisnah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Asthma UK and British Lung Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quint</LastName><ForeName>Jennifer K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>National Heart &amp; Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Asthma UK and British Lung Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brightling</LastName><ForeName>Chris E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Salman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurst</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>UCL Respiratory, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalmers</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeffer</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Barts Health NHS Trust and Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novotny</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drake</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heaney</LastName><ForeName>Liam G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, N Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudan</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Aziz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Soyza</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Population Health Science Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle, UK. Electronic address: anthony.de-soyza@newcastle.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International COVID-19 Airways Diseases Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_19004</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_19075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V027859/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Respir Med</MedlineTA><NlmUniqueID>101605555</NlmUniqueID><ISSNLinking>2213-2600</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Respir Med. 2021 Dec;9(12):1358-1360. doi: 10.1016/S2213-2600(21)00314-3</RefSource><PMID Version="1">34416190</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012120" MajorTopicYN="Y">Respiration Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests CEB reports grants from the Post-hospitalisation COVID-19 study during the conduct of the study. JRH reports personal fees and non-financial support from pharmaceutical companies (AstraZeneca and GlaxoSmithKline) that make medicines to treat chronic obstructive pulmonary disease, outside the submitted work. JDC reports grants and personal fees from AstraZeneca and Boehringer Ingelheim, and personal fees from GlaxoSmithKline, Insmed, Novartis, Chiesi, and Zambon, outside the submitted work. PEP reports personal fees and non-financial support from AstraZeneca, and a grant and non-financial support from GlaxoSmithKline, outside the submitted work. AS reports grants from the Health Data Research UK BREATHE Hub, the Medical Research Council, and the National Institute for Health Research, during the conduct of the study. ADS has received medical education grant support for BRONCH-UK, a UK bronchiectasis network, from GlaxoSmithKline, Gilead, Chiesi, and Forest labs, and his institution receives fees for his work as coordinating investigator on a phase 3 trial in bronchiectasis sponsored by Bayer. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Adeloye</LastName><ForeName>Davies</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elneima</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daines</LastName><ForeName>Luke</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poinasamy</LastName><ForeName>Krisnah</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quint</LastName><ForeName>Jennifer K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brightling</LastName><ForeName>Chris E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Salman</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurst</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chalmers</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeffer</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novotny</LastName><ForeName>Petr</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drake</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdollahi</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Dhiraj</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Lehebi</LastName><ForeName>Riyad</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayry</LastName><ForeName>Jagadeesh</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonay</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bont</LastName><ForeName>Louis J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourdin</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caramori</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Amy Hai Yan</ForeName><Initials>AHY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dockrell</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doe</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duckers</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Urzo</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ekstr&#xf6;m</LastName><ForeName>Magnus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esteban</LastName><ForeName>Crist&#xf3;bal</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greene</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Atul</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingram</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khoo</LastName><ForeName>Ee Ming</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ko</LastName><ForeName>Fanny Wai San</ForeName><Initials>FWS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koppelman</LastName><ForeName>Gerard H</ForeName><Initials>GH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipworth</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lisspers</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loebinger</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez-Campos</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maddocks</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mannino</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez-Garcia</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mcnamara</LastName><ForeName>Renae</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miravitlles</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ndarukwa</LastName><ForeName>Pisirai</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pooler</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rhee</LastName><ForeName>Chin Kook</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Dominick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tai</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulrik</LastName><ForeName>Charlotte Suppli</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heaney</LastName><ForeName>Liam G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudan</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Aziz</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Soyza</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>20</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34416191</ArticleId><ArticleId IdType="pmc">PMC8372501</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00286-1</ArticleId><ArticleId IdType="pii">S2213-2600(21)00286-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus disease dashboard. https://covid19.who.int/</Citation></Reference><Reference><Citation>Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8:1106&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7515601</ArticleId><ArticleId IdType="pubmed">32979987</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4693508</ArticleId><ArticleId IdType="pubmed">26755942</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Asthma Network  . Global Asthma Network; Auckland, New Zealand: 2018. The Global Asthma Report 2018.http://globalasthmareport.org/Global%20Asthma%20Report%202018.pdf</Citation></Reference><Reference><Citation>Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7424116</ArticleId><ArticleId IdType="pubmed">32817205</ArticleId></ArticleIdList></Reference><Reference><Citation>Skevaki C, Karsonova A, Karaulov A, Xie M, Renz H. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020;146:1295&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834224</ArticleId><ArticleId IdType="pubmed">33002516</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Government  COVID-19: long-term health effects. 2021. https://www.gov.uk/government/publications/covid-19-long-term-health-effects/covid-19-long-term-health-effects</Citation></Reference><Reference><Citation>World Health Organization  What we know about Long-term effects of COVID-19. 2020. https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update-36-long-term-symptoms.pdf?sfvrsn=5d3789a6_2 (in French).</Citation></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics  The prevalence of long COVID symptoms and COVID-19 complications. 2020. https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications</Citation></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, et al. &#x2018;Long-COVID&#x2019;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Hester KL, Macfarlane JG, Tedd H, et al. Fatigue in bronchiectasis. QJM. 2012;105:235&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">22016379</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wu F, Yi H, et al. Gender differences in chronic obstructive pulmonary disease symptom clusters. Int J Chron Obstruct Pulmon Dis. 2021;16:1101&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8068487</ArticleId><ArticleId IdType="pubmed">33907396</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslop K, Newton J, Baker C, Burns G, Carrick-Sen D, De Soyza A. Effectiveness of cognitive behavioural therapy (CBT) interventions for anxiety in patients with chronic obstructive pulmonary disease (COPD) undertaken by respiratory nurses: the COPD CBT CARE study: (ISRCTN55206395) BMC Pulm Med. 2013;13:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3827881</ArticleId><ArticleId IdType="pubmed">24498939</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010;35:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">20356988</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf8;rvik T, Br&#xe6;kkan SK, Enga K, et al. COPD and risk of venous thromboembolism and mortality in a general population. Eur Respir J. 2016;47:473&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">26585434</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res. 2021;31:365&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976723</ArticleId><ArticleId IdType="pubmed">33740207</ArticleId></ArticleIdList></Reference><Reference><Citation>Roig M, Eng JJ, Road JD, Reid WD. Falls in patients with chronic obstructive pulmonary disease: a call for further research. Respir Med. 2009;103:1257&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326069</ArticleId><ArticleId IdType="pubmed">19419852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemelli Against C-P-ACSG Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020;32:1613&#x2013;1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7287410</ArticleId><ArticleId IdType="pubmed">32529595</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudan I, El Arifeen S, Bhutta ZA, et al. Setting research priorities to reduce global mortality from childhood pneumonia by 2015. PLoS Med. 2011;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181228</ArticleId><ArticleId IdType="pubmed">21980266</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine O, Kosek M, Bhatnagar S, et al. Setting research priorities to reduce global mortality from childhood diarrhoea by 2015. PLoS Med. 2009;6:e41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653551</ArticleId><ArticleId IdType="pubmed">19278292</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudan I, Yoshida S, Chan KY, et al. Setting health research priorities using the CHNRI method: VII. A review of the first 50 applications of the CHNRI method. J Glob Health. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5481891</ArticleId><ArticleId IdType="pubmed">28685049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudan I, Yoshida S, Wazny K, Chan KY, Cousens S. Setting health research priorities using the CHNRI method: V. Quantitative properties of human collective knowledge. J Glob Health. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920010</ArticleId><ArticleId IdType="pubmed">27350873</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida S, Rudan I, Cousens S. Setting health research priorities using the CHNRI method: VI. Quantitative properties of human collective opinion. J Glob Health. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920008</ArticleId><ArticleId IdType="pubmed">27350874</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudan I, Yoshida S, Chan KY, et al. Setting health research priorities using the CHNRI method: I. Involving funders. J Glob Health. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576461</ArticleId><ArticleId IdType="pubmed">26401269</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida S, Cousens S, Wazny K, Chan KY. Setting health research priorities using the CHNRI method: II. Involving researchers. J Glob Health. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920006</ArticleId><ArticleId IdType="pubmed">27350870</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida S, Wazny K, Cousens S, Chan KY. Setting health research priorities using the CHNRI method: III. Involving stakeholders. J Glob Health. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4894379</ArticleId><ArticleId IdType="pubmed">27303649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudan I. Setting health research priorities using the CHNRI method: IV. Key conceptual advances. J Glob Health. 2016;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4938380</ArticleId><ArticleId IdType="pubmed">27418959</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudan I, Gibson JL, Ameratunga S, et al. Setting priorities in global child health research investments: guidelines for implementation of CHNRI method. Croat Med J. 2008;49:720&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2621022</ArticleId><ArticleId IdType="pubmed">19090596</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020;370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116472</ArticleId><ArticleId IdType="pubmed">32907855</ArticleId></ArticleIdList></Reference><Reference><Citation>Alqahtani JS, Njoku CM, Bereznicki B, et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. Eur Respir Rev. 2020;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9488450</ArticleId><ArticleId IdType="pubmed">32499306</ArticleId></ArticleIdList></Reference><Reference><Citation>Beurnier A, Jutant EM, Jevnikar M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur Respir J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7397950</ArticleId><ArticleId IdType="pubmed">32732333</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo JL, Almonacid C, Gonz&#xe1;lez Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7651839</ArticleId><ArticleId IdType="pubmed">33154029</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar MH, Panos RJ, Ko J, et al. Reliable adherence to a COPD care bundle mitigates system-level failures and reduces COPD readmissions: a system redesign using improvement science. BMJ Qual Saf. 2017;26:908&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">28733370</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D, Wirtheim E, Vetter P, et al. Long-term consequences of COVID-19: research needs. Lancet Infect Dis. 2020;20:1115&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462626</ArticleId><ArticleId IdType="pubmed">32888409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>